 Scott Garverick Carton Service - Packaging Insights Vice President Sales Visit Website |
As the vice president of Sales for Carton Service-Packaging Insights, Scott Garverick is responsible not only for the sales leadership of CS-PI’s cartoning division, but he also spearheads marketing and strategic alliances for the company’s pharmaceutical packaging arm. Garverick initiated CS-PI’s foray and implementation of the company’s venture into pharmaceutical contract packaging 12 years ago. His role with CS-PI began 23 years ago in an apprenticeship program in which he worked and trained in each CS-PI department. After completing the program, Garverick’s first 10 years of tenure were dedicated to generating new business for CS-PI. Garverick was then made an officer of the company and has been vice president of sales since 1996. Carton Service-Packaging Insights, which will be announcing its new corporate name this year, delivers original, turnkey contract and compliance packaging solutions for mid-sized and virtual pharmaceutical and nutraceutical companies throughout North America. CS-PI offers customers access to two in-house Design Teams, providing creative structural design solutions and innovative graphic designs.
|
Patient Compliance Packaging Q&A
-
Asked June 25th, 2009
This question would be best answered by a pharma company. The reason: from a packaging point of view, it would be difficult to speculate on any particular drug’s effectiveness and clinical usage. That said, here is the packaging side’s perspective:
When it comes to compliance packaging playing a role in establishing regimen effectiveness, the pharma companies would determine dosage and if necessary, titration needs. Then it would work with the pharma packager to develop the best means of assisting patient compliance and safety as well as assisting physicians’ control over and monitoring of patient dosing regimen. Assistance can come in the form of a daily annotated peel-and-push foiled package, an F=1 blister package, or any number of other structural design elements. It would again then fall to the drug company to use appropriate protocols and to establish benchmarks and effectiveness metrics to capture, build, and analyze unbiased, comparative data. Innovative packaging can then augment the pharma companies’ ability to be successful as they foster patient compliance.
